| CISL2304 | PMBCL | Real-world outcomes of patients with primary mediastinal large B-cell lymphoma in Korea: A multicenter, retrospective analysis
| PMBCL | Registry | Retrosp | 150 | Ongoing | | |
| CISL2303 | VR2 | A phase 1/2 study of the combination of venetoclax, rituximab and lenalidomide for relapsed or refractory primary central nervous system lymphoma | CNS | Salvage | Phase 1/2 | 35 | Preparing | 3 | 1 |
| CISL2302 | ZRICE | Phase I/II study of Zanubrutinib in combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide [ZR-ICE] in relapsed/refractory diffuse large B cell lymphoma | DLBCL | Salvage | Phase 1/2 | 72 | Ongoing | 12 | 1 |
| CISL2301 | SIENA | Phase 1/2 study of Selinexor in combination with ICE-D in patients with secondary CNS involving relapsed or refractory B-cell non-Hodgkin lymphoma | B-NHL | Salvage | Phase 1/2 | 35 | Ongoing | 3 | 1 |
| CISL2209 | PCNSL-R2P | Chemotherapy-free salvage therapy with rituximab, lenalidomide, and poseltinib for the treatment of relapsed or refractory primary central nervous system lymphoma | CNS | Salvage | Phase 2 | 29 | Ongoing | 5 | 1 |
| CISL2208 | DuoFOLK | Duodenal-type Follicular Lymphoma in Korean Population: A Multicenter Study | FL | Registry | Cohort | 245 | Ongoing | 42 | 8 |
| CISL2206 | TARANIS | Phase II study of Concurrent Tislelizumab and Radiotherapy for treatment-naive, newly diagnosed low-risk extranodal NK/T-cell lymphoma, nasal type | NK/T | 1st-line | Phase 2 | 38 | Ongoing | 14 | 6 |
| CISL2204 | BRM | A randomized phase II trial comparing rituximab/bendamustine (RB) alternating with rituximab/bendamustine/cytarabine (RBAC) with RB as induction therapy in elderly patients with newly diagnosed and transplant-ineligible mantle cell lymphoma | MCL | 1st-line | Phase 2R | 90 | Ongoing | 6 | 5 |
| CISL2203 | GPL | Phase II study of Glofitamab, Poseltinib and Lenalidomide in patients with relapsed/refractory diffuse large B cell lymphoma | DLBCL | Salvage | Phase 2 | 102 | Ongoing | 88 | 19 |
| CISL2202 | ACANTHUS | Multicenter, open label, phase I/II study of azacitidine-CHOP for patients with nodal T-cell lymphoma with T-follicular helper phenotype | TFHL | 1st-line | Phase 1/2 | 41 | Ongoing | 19 | 8 |
| CISL2201 | PCNSL-LEM | Phase II trial of Lenalidomide maintenance after high-dose methotrexate-based immunochemotherapy in patients with primary central nervous system lymphoma
| CNS | Maintenance | Phase 2 | 31 | Ongoing | 28 | 7 |
| CISL2104 | LARCH | Phase II study of lenalidomide-R-CHOP for patients with diffuse large B cell lymphoma who are at high risk of central nervous system relapse | DLBCL | 1st-line | Phase 2 | 100 | Ongoing | 95 | 11 |
| CISL2102 | ICING | Phase II study of Isatuximab and Cemiplimab in relapsed or refractory naturalkiller/T-cell lymphoid malignancy | NK/T | Salvage | Phase 2 | 37 | Ongoing | 38 | 7 |
| CISL2101 | RAINBOW | Prospective multi-center cohort study of newly diagnosed primary central nervous system lymphoma patients: Evaluation of tumor microenvironment by brain biopsy with multiplex immunohistochemistry | CNS | Registry | Cohort | 200 | Ongoing | 12 | 1 |
| CISL2004 | ICON | A prospective cohort of ibrutinib treatment for relapsed or refractory CLL with next-generation sequencing (NGS) assessment | CLL | Registry | Cohort | 30 | Ongoing | 31 | 7 |
| CISL2003 | BRIDGE | Brentuximab vedotin plus cisplatin, cytarabine, and dexamethasone in patients with relapsed or refractory Hodgkin’s lymphoma who are eligible for transplant. | HL | Salvage | Phase 2 | 30 | Ongoing | 3 | 3 |
| CISL2002 | OBICOM | Multicenter prospective Cohort study of combined chemotherapy with obinutuzumab and chlorambucil for elderly patients with chronic lymphocytic leukemia based on NGS assessment | CLL | Registry | Cohort | 31 | Ongoing | 34 | 9 |
| CISL1912 | D-GEMOX | Decitabine with Gemcitabine, Oxaliplatin for relapsed/refractory peripheral T cell lymphoma | PTCL | Salvage | Phase 2 | 66 | Ongoing | 14 | 6 |
| CISL1911 | HOLY | Multicenter retrospective study of elderly Hodgkin lymphoma | HL | Registry | Retrosp | 500 | Ongoing | 181 | 17 |
| CISL1905 | RRT-Allo | Allogeneic Stem Cell Transplantation with 3-days Busulfan plus fludarabine as Conditioning in Patients with Relapsed or Refractory T-, NK/T-cell lymphomas | PTCL | Salvage | Phase 2 | 34 | Ongoing | 20 | 10 |
| CISL1904 | AP MCLR | Asia-Pacific Multinational Registry of Mantle cell lymphoma | MCL | Registry | Cohort | 250 | Ongoing | 120 | 43 |
| CISL1902 | HOT | Multicenter Prospective Cohort Study of Hodgkin Lymphoma | HL | Registry | Cohort | 300 | Ongoing | 129 | 15 |
| CISL1901 | EPIC | A Phase II Study of Epigenetic Priming Using Azacitidine Followed by R-GDP in Patients with Transplant-Ineligible Relapsed/Refractory DLBCL | DLBCL | Salvage | Phase 2 | 27 | Ongoing | 15 | 7 |
| CISL1803 | BRAVO | A multi-center and non-interventional registry of Brentuximab Vedotin in patients with relapsed or refractory CD30+ lymphoma
| CD30+ | Salvage | Cohort | 150 | Ongoing | 85 | 12 |
| CISL1802 | FIXATION | A phase 2 study of ixazomib maintenance treatment for newly diagnosed mantle cell lymphoma | MCL | Maintenance | Phase 2 | 30 | Ongoing | 30 | 9 |
| CISL1801 | LEMONT | Phase II study of Lenalidomide Maintenance after Salvage therapy in patients with relapsed and/or refractory non-Hodgkin T-cell lymphoma (The LEMONT trial) | PTCL | Maintenance | Phase 2 | 79 | Ongoing | 58 | 11 |
| CISL | PMBCL | Real-world outcomes of patients with primary mediastinal large B-cell lymphoma in Korea: A multicenter, retrospective analysis
| PMBCL | Registry | Retrosp | 00 | Ongoing | | |